“…1,9,10 The actual, individual risk of thromboembolic events during JAKi treatment in dermatological indications is still very low. 11,12 The new safety assessment mainly concerns an increase in the general risk by coincident, independent risk factors for venous thromboembolism. 3 A relative contraindication for the use of JAKi would therefore apply primarily in cases of hereditary thrombophilia (such as APC resistance in Factor V Leiden mutation, hyperhomocysteinemia with polymorphism, prothrombin mutation, increased Factor VIII activity, and more rarely protein C deficiency, protein S deficiency, or antithrombin deficiency) as well as acquired thrombophilia (such as primary or secondary antiphospholipid syndrome, or severe liver dysfunction).…”